Activity Provided By:

ACHL

Advances in the Use of Checkpoint Inhibitors in the Treatment of Esophageal Cancer

Overview / Abstract:	Finally, after many years, esophageal cancer (EC) care is undergoing an evolution. Clinicians need to learn about the novel immunotherapies that have only recently been approved for EC. In this 24-minute video interview, Dr. Ashiq Masood, Director of Gastrointestinal Medical Oncology at Rush University Medical Center in Chicago, IL interviews Dr. Manish Shah Director of Gastrointestinal Oncology Program at Weill Cornell Medicine in New York, NY. They will discuss how to properly incorporate these newer agents with respect to the latest recommendations and guidelines. This activity will also highlight promising new data with these immunotherapies for frontline EC use.
Expiration	Nov 30, 2021
Discipline(s)	Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME
Format	Webinar / Webcast / Video
Credits / Hours	0.5
Accreditation	ACCME, ANCC
Presenters / Authors / Faculty	Ashiq Masood, MD (Interviewer) Director, Gastrointestinal Medical Oncology Co-Director, Rush Precision Oncology Program Assistant Professor of Medicine Division of Hematology, Oncology & Cell Therapy Rush University Medical Center Chicago, IL Manish Shah, MD (Interviewee) Director, Gastrointestinal Oncology Program Weill Cornell Medicine Chief, Solid Tumor Service Co-Director, Center for Advanced Digestive Disease NewYork-Presbyterian New York, NY
Activity Specialities / Related Topics	Gastroenterology / GI, Oncology / Cancer / Radiation Therapy, Surgery
Sponsors / Supporters / Grant Providers	Sponsored by Rush University Medical Center and the Academy for Continued Healthcare Learning (ACHL). Supported by an educational grant from Merck.
Keywords / Search Terms	ACHL Inhibitor, Esophageal Cancer, checkpoint, oncology, radiology, gastroenterology, squamous cell carcinomas, adenocarcinomas, chemotherapy, radiation, metastatic disease, toxicities, esophagus, Immune checkpoint inhibitors, pembrolizumab, nivolumab, ipilimumab, sintilimab, tislelizumab, PD-1 inhibitor, CTLA-4 inhibitor, biomarkers, monotherapy, chemotherapy, immunotherapy, irAEs, ATTRACTION-3 trial, NCCN guidelines, KEYNOTE-181 Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map